Pharmaceuticals News and Research

RSS

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

From Parexel 9 Nov 2009

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

9 Nov 2009

Researchers develop tools to visualize how different cell populations of cells communicate

Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Their study shows how bacteria talk to one another - an understanding that may lead to new therapeutic discoveries for diseases ranging from cancer to diabetes and allergies.

9 Nov 2009

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China.

9 Nov 2009

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

EpiCept Corporation today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.

9 Nov 2009

PhRMA releases statement regarding the House health care reform bill

We are disappointed, but not surprised by today's vote -- an uneasiness echoed by millions of hardworking Americans as well as nearly half of the members of the U.S. House of Representatives who voted against the bill.

9 Nov 2009

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

With his proposed health care reform plan, President Barack Obama has set his sights on cutting name-brand prescription drug costs by 50 percent for Medicare patients who fall into the "Part D" coverage gap, universally known as the "donut hole." Plan advocates rave about the potential cost-cutting and feel it's a promising start to health care reform.

7 Nov 2009

PPA bus tour raises awareness of patient assistance programs among state residents who are uninsured

The 'Help is Here Express' bus tour will be stopping in South Carolina and Georgia throughout the week of November 9-13 at various cities in order to help uninsured and financially-struggling patients access information on programs that provide prescription medicines for free or nearly free.

7 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

Biopharma companies need to incorporate innovative elements in their business models to survive healthcare reform

Those biopharmaceutical companies that are able to incorporate innovative and flexible elements into their business models will be best positioned to survive healthcare reform and maintain attractive long-term returns, according to a white paper published today by Cowen Healthcare Royalty Partners, a global healthcare private equity firm, and Health Advances, a leading healthcare strategy firm.

7 Nov 2009

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

7 Nov 2009

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

7 Nov 2009

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the company’s clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM).

7 Nov 2009

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

6 Nov 2009

GTC Biotherapeutics announces financial results for third quarter 2009

GTC Biotherapeutics, Inc.’s total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share, for the first nine months of 2008.

6 Nov 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

6 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

Neurogen announces financial results for the third quarter of 2009

Neurogen Corporation, a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009.

6 Nov 2009

Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.

6 Nov 2009

Pharmaceuticals News and Research

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Researchers develop tools to visualize how different cell populations of cells communicate

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

PhRMA releases statement regarding the House health care reform bill

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

PPA bus tour raises awareness of patient assistance programs among state residents who are uninsured

Locus Pharmaceuticals creates a new division, Ansaris

Biopharma companies need to incorporate innovative elements in their business models to survive healthcare reform

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GTC Biotherapeutics announces financial results for third quarter 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Neurogen announces financial results for the third quarter of 2009

Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

Industry Focus - Biopharma eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring